New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
On December 20, 2021, the FDA announced the approval of Eli Lilly’s Rezvoglar (insulin glargineaglr), a biosimilar to Sanofi’s Lantus® (insulin glargine).
Download PDF
Return to publications
